# Policy Convergence and the Future of Pharma Value Creation with  Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity

Page: https://stenobird.com/podcast/outcomes-rocket-769427/policy-convergence-and-the-future-of-pharma-value-creation-with-steve-mather-global-practice-lead-of-strategy-and-insight-at-lumanity
Text version: https://stenobird.com/podcast/outcomes-rocket-769427/policy-convergence-and-the-future-of-pharma-value-creation-with-steve-mather-global-practice-lead-of-strategy-and-insight-at-lumanity.md
Podcast: [Outcomes Rocket](https://stenobird.com/podcast/outcomes-rocket-769427)
Published: 2026-06-16T10:00:00+00:00
Episode link: https://pfx.vpixl.com/00edT/traffic.megaphone.fm/NSSMO8317230988.mp3
Audio file: https://pfx.vpixl.com/00edT/traffic.megaphone.fm/NSSMO8317230988.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/outcomes-rocket-769427/episodes/policy-convergence-and-the-future-of-pharma-value-creation-with-steve-mather-global-practice-lead-of-strategy-and-insight-at-lumanity
Duration seconds: 1501

## Resource

The future of market access belongs to organizations that plan years in advance. In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, explains why pharmaceutical companies must prepare now for major market access changes coming in Europe and beyond. He highlights that Joint Clinical Assessments for rare disease assets, beginning in 2028, will require earlier planning, stronger governance, and more integrated evidence-generation strategies. Steve also discusses the complexity created by varying country-specific care pathways, limited comparators, and the growing importance of real-world evidence in rare disease development. Across policy shifts like JCA, IRA, MFN, and new European pharmaceutical legislation, the central message is clear: organizations that anticipate earlier will be better positioned to succeed. Tune in to hear how the future of rare disease market access is being reshaped, and why companies that prepare earlier will have a major strategic advantage! Resources: Connect with and follow Steve Mather on LinkedIn. Follow Lumanity on LinkedIn and explore their website! Learn more about this series we're doing with Lumanity here: https://lumanity.com/commercialization-podcasts/

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/outcomes-rocket-769427/episodes/policy-convergence-and-the-future-of-pharma-value-creation-with-steve-mather-global-practice-lead-of-strategy-and-insight-at-lumanity/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/outcomes-rocket-769427/policy-convergence-and-the-future-of-pharma-value-creation-with-steve-mather-global-practice-lead-of-strategy-and-insight-at-lumanity.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.